



The First European Nanomedicine Mentoring Program Launches a New Edition Apply to boost your project development!

Paris, April 11th, 2017: The Nanomedicine Translation Advisory Board (nanomedTAB) offers since 2015 a free-of-charge mentoring program to assess, advise and accelerate promising nanomedicine projects to the market, based on the diverse experience of top skills industry experts. The objective? Help great projects and teams to get to commercial application faster and more reliably.

- √ 63 teams have already applied,
- √ from 16 countries in EU and beyond,
- ✓ half have been selected and are currently benefiting from coaching over time.

This **fifth edition** is open to companies, public and private research entities, and other organisations leading nanomedicine innovative projects in Europe.

The deadline for applications is the 24th of April 2017 (new deadline).

Selected projects will be invited to attend the **next TAB-In Sessions**, a series of face to face meetings with experts to be held on the **31**st of May **2017**, in <u>Gothenburg (Sweden)</u>, in the framework of the NanoMed North Annual Meeting 2017.

Applications should be submitted through the following link: www.nanomedtab.eu/?apply.

Further information about the NanomedTAB and its experts can be found at www.nanomedtab.eu.

ends

Contacts

TAB Manager Pedro SILVA <u>apsilva@tecminho.uminho.pt</u> Tel.: +351 253 510 596 ENATRANS Coordinator Nicolas GOUZE VDI/VDE-IT Nicolas.gouze@vdivde-it.de Tel.: +49 30 310078 209 ENATRANS Communication Sarah GAUBERT Violaine EMOURGEON sarah.gaubert@nanobiotix.com violaine.emourgeon@nanobiotix.com Tel.: + 33 1 75 44 69 42







About the ENATRANS project http://www.enatrans.eu

Enabling NAnomedicine TRANSlation, a Coordination and Support Action funded by the European Commission, has been built to help the translation of innovative projects related to nanomedicine to successfully go through the different stages of development from the idea to the patients and improve global knowledge on nanomedicine. ENATRANS is led by a consortium of 7 partners belonging to the European Technology Platform for Nanomedicine (ETPN): CEA-LETI (Grenoble, France), Nanobiotix SA (Paris, France), Gesellschaft fur Bioanalytik Muenster e.V. (Muenster, Germany), Tel-Aviv University (Tel-Aviv, Israel), Fondazione Don Carlo Gnocchi ONLUS (Milan, Italy), TecMinho (Braga, Portugal) and VDI/VDE-IT (Berlin, Germany).

About ETPN http://www.etp-nanomedicine.eu/public

Created in 2005, the European Technology Platform on Nanomedicine (ETPN), an initiative led by industry and set up together with the European Commission, is addressing the application of nanotechnology to achieve breakthroughs in healthcare. Its mission consists in building, shaping and supporting the European ecosystem of Nanomedicine. In 2015, the ETPN became an independent international Association under the French law 1901, with its Secretariat and headquarters located in Paris, France.

ETPN has developed solid and effective tools under the umbrella of the Nanomedicine Translation Hub aiming to select and help the development of the best innovative projects in Nanomedicine toward the clinic.

